



November 4, 2020

Company name: Mitsubishi Chemical Holdings Corporation
Representative: Hitoshi Ochi
Representative Corporate Executive Officer,
President & Chief Executive Officer
Listed on 1st section of TSE (stock code: 4188)
Contact: Osamu Shimizu
General Manager,
Public Relations and Investor Relations Office
TEL: [+81] (0)3-6748-7120

Notice Regarding the Recording of Impairment Loss

Mitsubishi Chemical Holdings Corporation hereby announces it recorded an impairment loss, as detailed below.

1. Details of the impairment loss

In the Health Care segment, the Company posted an ¥84.5 billion impairment loss on technology-related intangible assets (in-process research and development expenses) relating to development of a treatment for Parkinson's disease at NeuroDerm Ltd. This loss stemmed from a review of plans based on market research in view of expectations that this consolidated subsidiary's profitability would deteriorate in line with changes in the business climate.

2. Impact on the financial results

The aforementioned impairment loss has been reflected in the "Consolidated Financial Results for the First Half of the Fiscal Year Ending March 31, 2021" issued today.